Aggressive Variants of Castration-Resistant Prostate Cancer
Top Cited Papers
- 29 May 2014
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 20 (11), 2846-2850
- https://doi.org/10.1158/1078-0432.ccr-13-3309
Abstract
A subset of patients with advanced castration-resistant prostate cancer may eventually evolve into an androgen receptor (AR)–independent phenotype, with a clinical picture associated with the development of rapidly progressive disease involving visceral sites and hormone refractoriness, often in the setting of a low or modestly rising serum prostate-specific antigen level. Biopsies performed in such patients may vary, ranging from poorly differentiated carcinomas to mixed adenocarcinoma-small cell carcinomas to pure small cell carcinomas. These aggressive tumors often demonstrate low or absent AR protein expression and, in some cases, express markers of neuroendocrine differentiation. Because tumor morphology is not always predicted by clinical behavior, the terms “anaplastic prostate cancer” or “neuroendocrine prostate cancer” have been used descriptively to describe these rapidly growing clinical features. Patients meeting clinical criteria of anaplastic prostate cancer have been shown to predict for poor prognosis, and these patients may be considered for platinum-based chemotherapy treatment regimens. Therefore, understanding variants within the spectrum of advanced prostate cancer has important diagnostic and treatment implications. Clin Cancer Res; 20(11); 2846–50. ©2014 AACR.Keywords
This publication has 25 references indexed in Scilit:
- High Fidelity Patient-Derived Xenografts for Accelerating Prostate Cancer Discovery and Drug DevelopmentCancer Research, 2014
- Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine CarcinomaClinical Cancer Research, 2014
- Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate CancerCancer Discovery, 2013
- Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate CancerClinical Cancer Research, 2013
- Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cellsEndocrine-Related Cancer, 2007
- Synergy of p53 and Rb Deficiency in a Conditional Mouse Model for Metastatic Prostate CancerCancer Research, 2006
- Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate CancerScience, 2005
- CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial CellsCancer Research, 2004
- The polycomb group protein EZH2 is involved in progression of prostate cancerNature, 2002
- Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential.1995